A Phase II Eval of the Poly(ADP-Ribose)Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888)(NSC #737644) in the tx of Persistent or Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Ca in Patients who carry a germline BRCA 1 or 2 Mutation
Principal Investigator
Robert Coleman, MD
Status
Terminated
Date Opened To Accrual
April 09 2012
Date Closed to Accrual
November 15 2012
Date of Study Termination
January 27 2018
Disease Site
Gynecologic [GY]
Ovarian
Phase
II
Developmental Therapeutics
No
Primary Objective
To estimate the proportion of patients who have objective tumor response (complete or partial).
To determine the frequency and severity of adverse events associated with treatment with veliparib (ABT-888) as assessed by the Active Version of the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0.
Patient Population
Patients who have objective tumor response (complete or partial).
Target Accrual
51
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.